CHMP recommends Alexion's Soliris to treat myasthenia gravis

EMA’s CHMP recommended approval of an MAA from Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) for Soliris eculizumab to treat refractory generalized myasthenia gravis (MG) in patients who are anti-acetylcholine receptor (AChR) antibody positive...